Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer.
This brief review considers to what extent Magnetic Resonance Spectroscopy (MRS) can play a role in monitoring early tumour response with examples of preclinical studies and selected clinical studies in tumours of children and young adults. An early non-invasive indicator of tumour response to therapy would provide useful information regarding the effectiveness of therapy. This might be a relevant prognostic factor in new patients and in phase II studies could facilitate recommendations at an early stage as to whether to continue treatment. This review suggests that several markers and ratios are emerging as potential prognostic markers, but larger prospective studies are needed before translating this into clinical practice.
Vaidya
S J
SJ
Department of Paediatric Oncology, Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK.
Payne
Geoffrey S
GS
Leach
Martin O
MO
Pinkerton
C R
CR
D002648:Child; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009447:Neuroblastoma / Q000188:drug therapy / Q000378:metabolism; D010758:Phosphorus; D011522:Protons; D012509:Sarcoma / Q000188:drug therapy / Q000378:metabolism
D011522:Protons; D010758:Phosphorus